[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100542978":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":34,"responsibleParty":88,"collaborators":91,"id":96,"slug":97,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":20,"eligibilityCriteria":102,"healthyVolunteers":98,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":20,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adebrelimab arm","EXPERIMENTAL","Patients will receive induction chemotherapy with gemcitabine (1g\u002Fm2, d1 \\& 8 of every cycle) and cisplatin (80mg\u002Fm2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg\u002Fm2 will be administered every 3 weeks for 2 cycles during IMRT. Adebrelimab 1200mg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.",[13],"Drug: Adebrelimab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Adebrelimab","Drug: Adebrelimab Adebrelimab 1200mg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.\n\nOther Names:\n\nPD-L1 antibody\n\nDrug: Gemcitabine Gemcitabine 1g\u002Fm2, d1 \\& 8 of every cycle, every 3 weeks for 3 cycles before radiation.\n\nOther Names:\n\nGEM\n\nDrug: Cisplatin Induction cisplatin 80mg\u002Fm2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg\u002Fm2, every 3 weeks for 2 cycles during radiation\n\nOther Names:\n\nDDP\n\nRadiation: Intensity-modulated radiotherapy Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.\n\nOther Names:\n\nIMRT",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Jun Ma, M.D.","Sun Yat-Sen University Cancer Center","PRINCIPAL_INVESTIGATOR",[27,31],{"name":23,"role":28,"phone":29,"phoneExt":20,"email":30},"CONTACT","+862087343469","majun2@mail.sysu.edu.cn",{"name":32,"role":28,"phone":20,"phoneExt":20,"email":33},"Lei Chen, M.D.","chenlei@mail.sysu.edu.cn",[35,54,67,75],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"The First Affiliated Hospital of Xiamen University","RECRUITING","Xiamen","Fujian","361003","China","CN",{"type":44,"coordinates":45},"Point",[46,47],118.08187,24.47979,{"lat":47,"lon":46},[50],{"name":51,"role":28,"phone":52,"phoneExt":20,"email":53},"Sangang Wu, M.D.","0592-2132222","wusg@xmu.edu.cn",{"facility":55,"status":37,"city":56,"state":57,"zip":58,"country":41,"countryCode":42,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Nanfang Hospital, Southern Medical University","Guangzhou","Guangdong","510000",{"type":44,"coordinates":60},[61,62],113.25,23.11667,{"lat":62,"lon":61},[65],{"name":66,"role":28,"phone":20,"phoneExt":20,"email":20},"Jian Guan, M.D.",{"facility":68,"status":37,"city":56,"state":57,"zip":58,"country":41,"countryCode":42,"cosmosGeoPoint":69,"geoPoint":71,"contacts":72},"Sun Yat-sen University Cancer Center",{"type":44,"coordinates":70},[61,62],{"lat":62,"lon":61},[73],{"name":74,"role":28,"phone":29,"phoneExt":20,"email":30},"jun ma, M.D.",{"facility":76,"status":37,"city":77,"state":78,"zip":79,"country":41,"countryCode":42,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"West China Hospital, Sichuan University","Chengdu","Sichuan","610000",{"type":44,"coordinates":81},[82,83],104.06667,30.66667,{"lat":83,"lon":82},[86],{"name":87,"role":28,"phone":20,"phoneExt":20,"email":20},"Lei Liu, M.D.",{"type":25,"investigatorFullName":89,"investigatorTitle":90,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Jun Ma, MD","Principal Investigator",[92,93,95],{"name":55,"class":6},{"name":94,"class":6},"West China Hospital",{"name":36,"class":6},"100542978","phase-2-adebrelimab-and-chemoradiotherapy-in-high-risk-lanpc-100542978",false,"NCT06349889","Adebrelimab and Chemoradiotherapy in High-risk LANPC","Adebrelimab Combined with Chemoradiotherapy for High-risk Locoregionally Advanced Nasopharyngeal Carcinoma: a Phase 2, Multicenter, Single-arm Clinical Trial","Inclusion Criteria:\n\n1. Patients with histologically confirmed nasopharyngeal carcinoma.\n2. Tumor staged as IVA+T3N2M0 (AJCC 8th).\n3. Eastern Cooperative Oncology Group performance status ≤1.\n4. Adequate marrow function: neutrocyte count≥1.5×10e9\u002FL, hemoglobin ≥90g\u002FL and platelet count ≥100×10e9\u002FL.\n5. Alanine Aminotransferase (ALT)\u002FAspartate Aminotransferase (AST) ≤2.5×upper limit of normal (ULN), and bilirubin ≤ 1.5×ULN.\n6. Adequate renal function: creatinine clearance rate ≥ 60 ml\u002Fmin (Cockcroft-Gault formula).\n7. Patients must be informed of the investigational nature of this study and give written informed consent.\n8. Women of childbearing potential (WOCBP) who are sexually active must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of study drug. Men who are sexually active with WOCBP must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of the study drug\n\nExclusion Criteria:\n\n1. Age \\> 65 or \\\u003C 18.\n2. Hepatitis B surface antigen (HBsAg) positive and hepatitis B virus DNA \\>1×10e3 copies\u002Fml or 200IU\u002Fml\n3. Hepatitis C virus (HCV) antibody positive\n4. Has active autoimmune disease, except type I diabetes, hypothyroidism treated with replacement therapy, and skin disease that doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia).\n5. Has any condition that required systemic corticosteroid (equivalent to prednisone \\>10mg\u002Fd) or other immunosuppressive therapy within 28 days before informed consent. Patients received systemic corticosteroid equivalent to prednisone ≤10mg\u002Fd, inhale or topical corticosteroid will be allowed.\n6. Has a known history of active TB (bacillus tuberculosis) within 1 year; patients with adequately treated active TB over 1 year ago will be allowed.\n7. Has a known history of interstitial lung disease.\n8. Has received a live vaccine within 30 days before informed consent or will receive a live vaccine in the near future.\n9. Is pregnant or breastfeeding.\n10. Prior malignancy within 5 years, except in situ cancer, adequately treated non-melanoma skin cancer, and papillary thyroid carcinoma.\n11. Has known allergy to large molecule protein products or any compound of Adebrelimab.\n12. Has a known history of human immunodeficiency virus (HIV) infection.\n13. Any other condition, including symptomatic heart failure, unstable angina, myocardial infarction, active infection requiring systemic therapy, mental illness or domestic\u002Fsocial factors, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results.","ALL","18 Years","65 Years",{"count":107,"type":108},50,"ESTIMATED","INTERVENTIONAL",[111],"PHASE2","This trial aims to study the role of Adebrelimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) for high-risk locoregionally advanced nasopharyngeal carcinoma(LANPC).",[114,115],"Nasopharyngeal Carcinoma","Nasopharyngeal Cancer",[117,118,119],"immunotherapy","Chemoradiotherapy","PD-L1","2025-01-13",{"date":122,"type":123},"2025-01-15","ACTUAL",{"date":125,"type":123},"2024-07-23",{"date":127,"type":108},"2028-05-01",{"name":5,"class":6},4]